title: Long-term durability of response to adalimumab in Crohn's disease.
abstract: BACKGROUND
  Adalimumab is an effective treatment for Crohn's disease (CD), but may also be associated with loss of response. Few reports provide insight into the durability of treatment of CD with adalimumab for periods longer than 12 months in clinical practice.
  
  
  OBJECTIVE
  To evaluate the long-term durability of adalimumab maintenance treatment and to identify predictive factors associated with loss of response.
  
  
  METHODS
  CD patients who initially responded to adalimumab were evaluated in a historical cohort study. Maintenance of long-term response was estimated using Kaplan-Meier analysis. Cox regression analysis was performed to identify potential predictive factors for loss of efficacy.
  
  
  RESULTS
  In all, 380 CD patients were included (mean age, 38 years; 52% female). Of these, 43% had ileocolic CD, 50% inflammatory CD, and 41% perianal CD. Median follow-up with adalimumab was 8 months (range, 4-75 months). The annual risk of loss of response to adalimumab was 18% per patient-year of follow-up. Twenty-eight percent of patients were anti-TNF-naïve and 72% anti-TNF-experienced. The loss of efficacy was 8% per patient-year of follow-up in the anti-TNF-naïve patients and 22% in the anti-TNF-experienced group (P < 0.01). In the multivariate analysis, the presence of extraintestinal manifestations (hazard ratio [HR] = 1.7; 95% confidence interval [CI] = 1.02-2.9) and previous experience with other anti-TNF agents (HR = 2.5,95% CI = 1.2-5.3) were associated with higher risk of loss of efficacy.
  
  
  CONCLUSIONS
  A relevant proportion of CD patients on long-term adalimumab lost response. The risk of loss of response was higher (more than 2-fold) in anti-TNF-experienced than in anti-TNF-naïve patients (22% vs. 8% per patient-year of treatment). Having extraintestinal manifestations seems to increase the risk of loss of efficacy.
authors: Gastroenterology Units of Hospital de La Princesa and Instituto de Investigación Sanitaria Princesa, IP, Madrid, Spain. mariachs2005@gmail.com
authors: M
authors: M
authors: Chaparro
authors: J
authors: J
authors: Panés
authors: V
authors: V
authors: García
authors: O
authors: O
authors: Merino
authors: P
authors: P
authors: Nos
authors: E
authors: E
authors: Domènech
authors: M
authors: M
authors: Peñalva
authors: E
authors: E
authors: García-Planella
authors: M
authors: M
authors: Esteve
authors: J
authors: J
authors: Hinojosa
authors: M
authors: M
authors: Andreu
authors: F
authors: F
authors: Muñoz
authors: A
authors: A
authors: Gutiérrez
authors: J L
authors: JL
authors: Mendoza
authors: J
authors: J
authors: Barrio
authors: M
authors: M
authors: Barreiro-de
authors: I
authors: I
authors: Vera
authors: P
authors: P
authors: Vilar
authors: J L
authors: JL
authors: Cabriada
authors: M A
authors: MA
authors: Montoro
authors: X
authors: X
authors: Aldeguer
authors: C
authors: C
authors: Saro
authors: J P
authors: JP
authors: Gisbert